<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474161</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-111-7</org_study_id>
    <secondary_id>2011-004723-13</secondary_id>
    <nct_id>NCT01474161</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505</brief_title>
  <official_title>Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SGS Aster S.A.S.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naturalpha</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to&#xD;
      compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60&#xD;
      mg GFT505) and the old GFT505 formulation (capsule dosed at 20 mg GFT505) in healthy male&#xD;
      subjects and to assess the impact of gender on this relative bioavailability after&#xD;
      administration in male and female subjects.&#xD;
&#xD;
      Using the new formulation, a single and a multiple ascending dose study will be performed in&#xD;
      overweight or obese male subjects otherwise healthy whose demographic and physiological&#xD;
      characteristics are thought to be closer to those of the target population (Type 2 diabetes).&#xD;
      Thereafter, a group of male and female patients with Type 2 diabetes will receive multiple&#xD;
      dose administration of GFT505.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be divided in 4 successive parts :&#xD;
&#xD;
        -  Study Part I will be a comparative bioavailability between a new GFT505 formulation&#xD;
           (capsule dosed at 60 mg GFT505 by capsule) and the old GFT505 formulation (capsule dosed&#xD;
           at 20 mg GFT505 by capsule) coupled with an evaluation of the gender effect assessed&#xD;
           with the new formulation. In this purpose a group of 12 male subjects will receive&#xD;
           successively both formulations on a unique occasion in a randomized manner while a group&#xD;
           of 12 female subjects will receive the new formulation on one occasion only. This part&#xD;
           of the study will be done in healthy volunteers.&#xD;
&#xD;
        -  Study Part II will be a single ascending dose to be run at a maximum of 3 dose levels.&#xD;
           Subjects included in this part of the study will receive only one dose level to limit&#xD;
           the exposure to GFT505. Three cohorts of 8 subjects are planned to be included. This&#xD;
           part will be run in overweight or obese subjects.&#xD;
&#xD;
        -  Study Part III will start after completion of the first Cohort of Study Part II. Study&#xD;
           Part III will be a multiple ascending dose to be run at a maximum of 3 dose levels.&#xD;
           Subjects included in this part of the study will receive only one dose level to limit&#xD;
           the exposure to GFT505. Three cohorts of 12 subjects are planned to be included. This&#xD;
           part will be run in overweight or obese subjects.&#xD;
&#xD;
        -  Study Part IV will follow the same design and same treatment schedule than Study Part&#xD;
           III but will be performed in the target population, patients with Type 2 diabetes and&#xD;
           only one dose will be tested in study part IV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters (Study Part I)</measure>
    <time_frame>24h post-dose</time_frame>
    <description>For each subject at each Treatment Period, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety parameters (Study Parts II, III and IV)</measure>
    <time_frame>Part II : 5 days ; Part III : 20 days ; Part IV : 20 days</time_frame>
    <description>Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters (Study Part I)</measure>
    <time_frame>12 days for male and 5 days for female</time_frame>
    <description>Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters (Study Parts II, III and IV)</measure>
    <time_frame>Part II : 24h post-dose ; Part III : 15 days ; Part IV : 15 days</time_frame>
    <description>Study Part II : For each subject of each dose level, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose.&#xD;
Study Part III and Study Part IV : Assuming a once daily administration, blood will be collected at the following time points:&#xD;
Day 1 pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose.&#xD;
Days 3, 7, 10, 11, 12 and 13 pre-dose.&#xD;
Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Obese</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GFT505 20mg - old formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Part I : dose level = 120mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFT505 60mg - new formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 120mg - old formulation</intervention_name>
    <description>hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.</description>
    <arm_group_label>GFT505 20mg - old formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 120mg - new formulation</intervention_name>
    <description>hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.</description>
    <arm_group_label>GFT505 60mg - new formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 180mg - new formulation</intervention_name>
    <description>hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.</description>
    <arm_group_label>GFT505 60mg - new formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 240mg - new formulation</intervention_name>
    <description>hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.</description>
    <arm_group_label>GFT505 60mg - new formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 300mg - new formulation</intervention_name>
    <description>hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.</description>
    <arm_group_label>GFT505 60mg - new formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part I :&#xD;
&#xD;
          -  Male or female healthy volunteers 18 to 45 years of age (inclusive).&#xD;
&#xD;
          -  Subjects with a body mass index (BMI) ≥ 18 and ≤ 28 kg/m2 at screening.&#xD;
&#xD;
          -  For female subjects of childbearing potential, use of double contraception method.&#xD;
&#xD;
          -  Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not&#xD;
             clinically significant by the principal Investigator.&#xD;
&#xD;
        Part II and III :&#xD;
&#xD;
          -  Male healthy volunteers 18 to 55 years of age (inclusive).&#xD;
&#xD;
          -  Subjects with a BMI &gt;28 and &lt;35 kg/m2 at screening.&#xD;
&#xD;
          -  Normal arterial BP and pulse rate or, if abnormal, considered not clinically&#xD;
             significant by the principal Investigator.&#xD;
&#xD;
        Part IV :&#xD;
&#xD;
          -  Male or female Type 2 diabetic patients 18 to 60 years of age.&#xD;
&#xD;
          -  Females participating in the study must be either of non-child bearing potential or&#xD;
             using an efficient double contraception.&#xD;
&#xD;
          -  Currently treated with any antidiabetic treatment (a maximum of two anti-diabetic&#xD;
             drugs including metformin in all cases) with the exception of insulin or GLP analogs&#xD;
             and agonists therapy.&#xD;
&#xD;
          -  Stable diabetes with glycosylated hemoglobin (HbA1c) &lt; or =10% or less.&#xD;
&#xD;
          -  Normal renal function as defined by a creatine clearance &gt;90 mL/min calculated with&#xD;
             the Cockcroft-Gault formula.&#xD;
&#xD;
          -  Subjects with a BMI from 18 to 32 kg/m2 at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part I :&#xD;
&#xD;
          -  Who previously received GFT505.&#xD;
&#xD;
          -  With any clinically significant abnormality following review of prestudy laboratory&#xD;
             tests (Aspartate and Alanine aminotransferase must be within normal ranges), vital&#xD;
             signs, full physical examination and Electrocardiogram.&#xD;
&#xD;
          -  Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or&#xD;
             anti-HIV 1/2 (Human immunodeficiency virus) or anti-HCV (Hepatitis C virus)&#xD;
             antibodies.&#xD;
&#xD;
          -  Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per&#xD;
             week, one unit = 8 g or about 10 mL of pure alcohol).&#xD;
&#xD;
          -  Who drink more than 8 cups daily of beverage containing caffeine.&#xD;
&#xD;
          -  Who have a positive laboratory test for urine drug screening (opiates, cocaine,&#xD;
             amphetamine, cannabis, benzodiazepines).&#xD;
&#xD;
          -  Who have undergone surgery or have donated blood within 12 weeks prior to the start of&#xD;
             the study.&#xD;
&#xD;
          -  Who have taken any prescribed or over the counter drug (including antacid drug), with&#xD;
             the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first&#xD;
             dose administration.&#xD;
&#xD;
        Part II and III : specific additional exclusion criteria&#xD;
&#xD;
        - Who have taken fibrates within 6 weeks prior to the first dose administration.&#xD;
&#xD;
        Part IV : specific additional exclusion criteria&#xD;
&#xD;
          -  With unstable proliferative retinopathy, macular oedema (fundus examination performed&#xD;
             in the previous year will be considered relevant on Investigator's judgement).&#xD;
&#xD;
          -  Who have taken fibrates within 6 weeks prior to the first dose administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémy Hanf, Development Director</last_name>
    <role>Study Director</role>
    <affiliation>GENFIT, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Betting, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Aster S.A.S., Phase I Clinical Unit, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Aster S.A.S. - Phase I Clinical Unit</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <last_update_submitted>November 23, 2012</last_update_submitted>
  <last_update_submitted_qc>November 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

